Spyre Therapeutics reports positive data for UC treatment
Biotechnology company Spyre Therapeutics has reported positive results for its treatment for moderate-to-severely-active ulcerative colitis (UC).
SPY001, a potential best-in-class anti-α4β7, met its primary endpoint in a Phase II trial, with a significant reduction of 9.2 points from baseline at Week 12 in Robart’s Histopathology Index (RHI) score.
Results announced show SPY001 was well tolerated with a safety profile consistent with the α4β7 class.
“SPY001 was designed to improve upon vedolizumab’s proven activity in IBD [inflammatory bowel disease (IBD) by matching its epitope and potency while increasing target coverage through an extended half-life and greater induction dosing,” said Deanna Nguyen, SVP of Clinical Development at Spyre Therapeutics and SKYLINE study lead.
“Our data today support the hypothesis that this approach could lead to a best-in-class anti-α4β7 product across safety, efficacy, and convenience. Beyond SPY001’s potential as a monotherapy, we continue to believe that its gut-selective mechanism makes it an ideal backbone for combination therapy alongside our cytokine-targeting investigational antibodies SPY002 (anti-TL1A) or SPY003 (anti-IL23).
“We have begun enrolling these combinations globally and look forward to unveiling proof-of-concept data next year.”
